|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Deregulation of the expression of these interleukins was shown to be responsible for various diseases, such as i) IL-4 vs. immediate type hypersensitivity and ii) IL-6 vs. autoimmunity and multiple myelomas.
|
8691054 |
1989 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The IL-6 gene but not the IL-6 receptor gene is occasionally rearranged in patients with multiple myeloma.
|
1695702 |
1990 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glucocorticoids significantly inhibited proliferation of myeloma cells, and decreased the messenger RNA (mRNA) expressions of interleukin-6 (IL-6) and secretory type immunoglobulin G (IgG).
|
2297574 |
1990 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the hepatoma line PLC/PRF/5, which contains 2,300 IL6 receptors, was more sensitive to IL6-PE40 (amount of protein required to inhibit protein synthesis by 50% was 5 ng/ml) than both the myeloma cell lines U266 and H929 (for both cell lines, the 50% inhibitory dose was 8 ng/ml), which contain 15,500 and 16,500 IL6 receptors, respectively.
|
2160579 |
1990 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Northern blot analysis revealed that the growth inhibition of the IL-6-dependent MM cell line U-1958 was not due to down-regulation of IL-6 receptor mRNA expression and that the differential sensitivity to IFN-gamma was not due to differences in IFN-gamma receptor expression.
|
1826658 |
1991 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A definitive separation of both putative sources for IL-6 may be difficult to achieve in fresh patient IL-6 growth requirement and production by pure myeloma cell populations using seven human myeloma cell lines (OCI-My 1 to 7) that were established from patients with advanced disease.
|
1912582 |
1991 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 has been shown to be a plasmacytoma growth factor in mice and is believed to play a key role in the development of human multiple myeloma.
|
1864979 |
1991 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266.
|
1991169 |
1991 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present data give a clear-cut demonstration of the paracrine origin of IL 6 in vivo in human MM.
|
2060582 |
1991 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that the response to IL-6 is heterogeneous among the MM lines and that IL-6 acts as a paracrine growth factor for two of six lines.
|
1707469 |
1991 |
|
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The establishment of an interleukin-6-dependent myeloma cell line (FLAM-76) carrying t(11;14)(q13;q32) chromosome abnormality from an aggressive nonsecretory plasma cell leukemia.
|
1516003 |
1992 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The supernatants of the cell line were also tested on the IL-6 sensitive human myeloma line OCI-My4 and myeloma colonies grew in response.
|
1493476 |
1992 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine whether the receptor for IL-6 may exist as a soluble molecule, RNA was analysed from the transformed B-cell lines U266, CESS and Daudi, from bone marrow from two myeloma patients, and from normal leukocytes.
|
1633265 |
1992 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we devised a model of IL-6 autocrine growth in vitro by transfecting IL-6 cDNA into a human myeloma cell line that had a proliferative response to IL-6 but did not produce IL-6.
|
1568457 |
1992 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The direct effect of IL-6 on IL-6 receptor gene expression in myeloma cells was further confirmed by adding IL-6 to an autonomously growing myeloma cell line.
|
1587349 |
1992 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A human multiple myeloma (MM) cell line, U-266, has developed the ability to grow independently of exogenous interleukin 6 (IL-6) during long-term cultivation in vitro.
|
1588793 |
1992 |
|
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Abnormal expression of the IL-6 gene has been suggested to be involved in the pathogenesis of a variety of diseases, especially rheumatoid arthritis, Castleman's disease, mesangial proliferative glomerulonephritis, multiple myeloma and Kaposi's sarcoma.
|
1643291 |
1992 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that, among cytokines shown to control myeloma-cell growth in vitro, IL-1, IL-6 and G-CSF could play a role in the development of myeloma disease in vivo.
|
7510989 |
1993 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro.
|
8499642 |
1993 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since both IL-6 and bcl-2 protein have been shown to prevent programmed cell death, this may be the unifying event in MM.
|
8467229 |
1993 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To investigate the source and target cells of IL-6 activity in multiple myeloma, expression of the cytokine and its receptor genes by myeloma plasma cells was studied.
|
8507873 |
1993 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 (IL-6) is a differentiation and growth factor for a variety of cell types and its excessive production plays a major role in the pathogenesis of multiple myeloma and post-menopausal osteoporosis.
|
7813426 |
1994 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IFN-alpha-mediated decrease of gp80 levels was not detected on IL-6-independent myeloma (RPMI 8226) or myeloid cells (U937).
|
7989587 |
1994 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin 6 (IL-6) is a major growth factor for tumor plasma cells involved in human multiple myeloma (MM).
|
8145045 |
1994 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The pleiotropic cytokine interleukin 6 (IL-6) plays a role in the pathogenesis of various diseases, such as multiple myeloma, autoimmune and inflammatory diseases and osteoporosis.
|
7964514 |
1994 |